NUVALENT INC
NASDAQ: NUVL (Nuvalent, Inc.)
Last update: 11 hours ago123.43
0.07 (0.06%)
| Previous Close | 123.36 |
| Open | 123.40 |
| Volume | 3,945,950 |
| Avg. Volume (3M) | 1,995,075 |
| Market Cap | 9,766,798,336 |
| Price / Book | 8.31 |
| 52 Weeks Range | |
| Earnings Date | 6 Aug 2026 |
| Diluted EPS (TTM) | -4.42 |
| Current Ratio (MRQ) | 14.48 |
| Operating Cash Flow (TTM) | -203.80 M |
| Levered Free Cash Flow (TTM) | -98.58 M |
| Return on Assets (TTM) | -22.23% |
| Return on Equity (TTM) | -35.69% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Nuvalent, Inc. | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 2.0 |
| Insider Activity | -3.0 |
| Price Volatility | -3.0 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | 4.0 |
| Average | -0.50 |
|
Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company’s operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically validated kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 2.85% |
| % Held by Institutions | 110.02% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Deerfield Management Company, L.P. | 31 Mar 2026 | 17,248,450 |
| Paradigm Biocapital Advisors Lp | 31 Mar 2026 | 5,324,433 |
No data within this time range.
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| BOGLE GRANT C. | 123.39 | - | 3,444 | 424,955 |
| MEYERS MICHAEL L. | 123.39 | - | 3,444 | 424,955 |
| NOCI DARLENE | - | 123.25 | -20,000 | -2,465,000 |
| OLIGER CHRISTY J. | 123.39 | - | 3,444 | 424,955 |
| PORTER JAMES RICHARD | - | 88.49 | -30,000 | -2,654,700 |
| PROTOPAPAS ANNA | 123.39 | - | 3,444 | 424,955 |
| SQUARER RON | 123.39 | - | 3,444 | 424,955 |
| SRIVASTAVA SAPNA | 123.39 | - | 3,444 | 424,955 |
| WHEELER CAMERON | 123.39 | - | 3,444 | 424,955 |
| Aggregate Net Quantity | -25,892 | |||
| Aggregate Net Value ($) | -2,145,014 | |||
| Aggregate Avg. Buy ($) | 123.39 | |||
| Aggregate Avg. Sell ($) | 105.87 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| BOGLE GRANT C. | Director | 16 Jun 2026 | Acquired (+) | 3,444 | 123.39 | 424,955 |
| MEYERS MICHAEL L. | Director | 16 Jun 2026 | Acquired (+) | 3,444 | 123.39 | 424,955 |
| OLIGER CHRISTY J. | Director | 16 Jun 2026 | Acquired (+) | 3,444 | 123.39 | 424,955 |
| PROTOPAPAS ANNA | Director | 16 Jun 2026 | Acquired (+) | 3,444 | 123.39 | 424,955 |
| SQUARER RON | Director | 16 Jun 2026 | Acquired (+) | 3,444 | 123.39 | 424,955 |
| SRIVASTAVA SAPNA | Director | 16 Jun 2026 | Acquired (+) | 3,444 | 123.39 | 424,955 |
| WHEELER CAMERON | Director | 16 Jun 2026 | Acquired (+) | 3,444 | 123.39 | 424,955 |
| NOCI DARLENE | Officer | 09 Jun 2026 | Automatic sell (-) | 20,000 | 123.25 | 2,465,000 |
| NOCI DARLENE | Officer | 09 Jun 2026 | Option execute | 20,000 | - | - |
| PORTER JAMES RICHARD | Officer | 08 Jun 2026 | Automatic sell (-) | 30,000 | 88.49 | 2,654,700 |
| PORTER JAMES RICHARD | Officer | 08 Jun 2026 | Option execute | 30,000 | - | - |
| Show more | ||||||
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |